EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Toward end-to-end continuous biopharmaceutical manufacturing: Current advances and prospects

Seonbong Lee, Taehyeon Kim, Jimin Kang, Jueun Lee, Dongkyu Kim, Young Hyun Cho, Han Bit Kim, Jong Uk Park, Jong Youn Baik, Youngbin Baek, Moo Sun Hong

New Biotechnology · 2026-09 · 94 · 192-214

DOI: 10.1016/j.nbt.2026.06.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New Biotechnology, 2026-09. Verfasst von Seonbong Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea. Hauptthemen laut MEDLINE: Biological Products, Biotechnology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agricultural Science and Technology Innovation Program, Korea Ministry of Trade Industry and Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

End-to-end continuous biopharmaceutical manufacturing extends process intensification from improved standalone unit operations to integrated process trains designed for long-duration operation with minimal pooling. This review synthesizes recent progress across upstream and downstream processing and frames end-to-end continuity as a system-level integration and interface-engineering problem in which throughput, residence-time behavior, and quality are jointly managed. Upstream perfusion sustains high viable cell density and productivity, but it tightens constraints on critical process parameters and demands robust monitoring to deliver a consistent feed. In downstream processing, continuous capture and polishing, continuous conditioning, and continuous-compatible viral clearance steps are increasingly feasible. However, long-duration robustness, cyclic dynamics, and sensitivity to feed variability remain central considerations. Across integration case studies, the dominant barrier is not missing unit operations but unresolved interface mismatches, especially between steady upstream harvest and cyclic downstream operations, that drive surge and hold requirements unless engineered out through residence-time and cycle-time synchronization, in-line conditioning, and long-duration filtration performance management. In addition, process analytical technologies and digital twins underpin real-time observability and control, while ultra scale-down and high-throughput development workflows accelerate operating-window definition and generate data for model calibration and control design. Overall, practical end-to-end continuity depends on coordinated advances in interface engineering, platform-level integration, and credible validation strategies for extended continuous operation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsBiotechnologyBioreactors

Stichwörter der Autor:innen

Continuous biomanufacturingDigital twinInterface engineeringProcess analytical technologyProcess integrationResidence-time distributionUltra scale-down

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea.
  • Department of Chemical and Biological Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
  • Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea; Department of Biological Engineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon…
  • Department of Chemical and Biological Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea. Electronic address: moosun@snu.ac.kr.

Förderung

  • Agricultural Science and Technology Innovation Program
  • Korea Ministry of Trade Industry and Energy

Zitieren

APA

Lee, S., Kim, T., Kang, J., Lee, J., Kim, D., Cho, Y. H., Kim, H. B., Park, J. U., Baik, J. Y., Baek, Y., & Hong, M. S. (2026). Toward end-to-end continuous biopharmaceutical manufacturing: Current advances and prospects. New Biotechnology, 94, 192-214. https://doi.org/10.1016/j.nbt.2026.06.002

Vancouver

Lee S, Kim T, Kang J, Lee J, Kim D, Cho YH, et al. Toward end-to-end continuous biopharmaceutical manufacturing: Current advances and prospects. New Biotechnology. 2026;94:192-214. doi:10.1016/j.nbt.2026.06.002

BibTeX
@article{Lee2026,
  author = {Lee, Seonbong and Kim, Taehyeon and Kang, Jimin and Lee, Jueun and Kim, Dongkyu and Cho, Young Hyun and Kim, Han Bit and Park, Jong Uk and Baik, Jong Youn and Baek, Youngbin and Hong, Moo Sun},
  title = {Toward end-to-end continuous biopharmaceutical manufacturing: Current advances and prospects},
  journal = {New Biotechnology},
  year = {2026},
  volume = {94},
  pages = {192--214},
  doi = {10.1016/j.nbt.2026.06.002}
}
Kostenlos starten →